Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10
CA 2250164 C · Owner: Coggin, Joseph H. · Inventors: Barsoum, Adel L.; Coggin, Joseph H.; Rohrer, James W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a method of determining the success of a cancer therapy in an individual, comprising the step of measuring the frequency of occurrence of an oncofetal antigen-specific subclasses in the individual's peripheral blood. Also provided is a method of determining whether protective immunity against a tumor will develop in an individual comprising the step of , measuring the frequency of oncofetal antigen-specific T cells tumor cells and , macrophages at the site of the tumor which secrete IL-10. Additionally a , method of determining whether an individual having a tumor will go into remission or remain in remission, comprising the step of measuring the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 4, 1997 and granted December 6, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 4, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 4, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.